Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine for cognitive impairment in adults with HIV
IRCT20130719014054N3Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivastigmine in HIV encephalopathy (HAND) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Cognitive function efficacy and safety, Rate of cognitive impairment and 1 more. Started Aug 2024; status: completed.
02
Drugs
rivastigmine
03
Conditions
HIV encephalopathy (HAND)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on IRCT20130719014054N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130719014054N3.